Short treatment with the tumour necrosis factor-α blocker infliximab diminishes chronic chagasic myocarditis in rats without evidence of Trypanosoma cruzi reactivation

DSpace/Manakin Repository

Show simple item record

dc.creator Pérez, Ana Rosa
dc.creator Fontenella, Germán Héctor
dc.creator Nocito, Ana Lía
dc.creator Revelli, Silvia
dc.creator Bottasso, Oscar
dc.date.accessioned 2014-11-12T18:07:01Z
dc.date.available 2014-11-12T18:07:01Z
dc.date.issued 2009-08
dc.identifier.issn 1365-2249 es
dc.identifier.uri http://hdl.handle.net/2133/3636
dc.description Tumour necrosis factor (TNF)-α is crucial for resistance to Trypanosoma cruzi acute infection, but there is scant information on its role during the chronic phase. To address this issue, we analysed whether a short treatment with a TNF-α blocker affected the course and characteristics of chronic disease in a rat experimental model of T. cruzi infection. An anti-TNF-α agent (infliximab) was administered during the chronic phase for a period of 4 weeks (3 mg/kg/week), while control infected rats were inoculated with saline physiological solution. Search for parasites yielded non-successful results in all infected groups, irrespective of treatment. Nevertheless, the presence of T. cruzi kDNA in heart tissue was detected in infected and infected plus treated animals. Because infliximab might induce changes in the anti-parasite cytokine response, circulating levels of interleukin (IL)-10, interferon-gamma and nitric oxide were evaluated. An increase in IL-10 levels was observed only in the infected group treated with the anti-TNF-α blocker compared to the remaining groups (P < 0·05). A clear attenuation of histological damage associated with a diminution of cardiac TNF-α mRNA expression was observed in the infected and treated animals compared to the infected and non-treated group. Blocking of TNF-α during a relatively short period in chronically infected rats did not lead to evident parasite reactivation but reduced myocarditis severity significantly, indicating a role of this cytokine in the pathogenesis of chronic myocardial damage. es
dc.description.sponsorship This work was supported by grants from Secretariat for Science and Technology (SECYT-UNR), Josefina Prats Foundation and Fellowship of Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). es
dc.format application/pdf
dc.format.extent 291–299 es
dc.language.iso eng
dc.publisher British Society for Immunology es
dc.rights openAccess
dc.subject Chagas' reactivation es
dc.subject Chronic chagasic myocarditis es
dc.subject Infliximab treatment es
dc.subject Trypanosoma cruzi es
dc.subject Tumour necrosis factor-α es
dc.title Short treatment with the tumour necrosis factor-α blocker infliximab diminishes chronic chagasic myocarditis in rats without evidence of Trypanosoma cruzi reactivation es
dc.type article
dc.type artículo
dc.type publishedVersion
dc.rights.holder © 2009 British Society for Immunology es
dc.relation.publisherversion doi:10.1111/j.1365-2249.2009.03946.x es
dc.citation.title Clinical and Experimental Immunology es
dc.citation.volume 157 es
dc.description.fil Fil: Pérez, Ana Rosa. Instituto de Inmunologia, Facultad de Ciencias Médicas de Rosario, Universidad Nacional de Rosario, Argentina es
dc.type.collection articulo


Files in this item

This item appears in the following Collection(s)

Show simple item record

My Account


Search DSpace


Browse

Statistics